drugset
drugset / Trial / NCT06054113

Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

NCT06054113 ↗

Phase 2 Active not recruiting 18 enrolled Amgen
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the efficacy of blinatumomab.

Timeline

Start
2024-07-23
Primary completion
2026-01-05
Completion
2027-10-14

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Blinatumomab Monoclonal antibody — Intravenous

Indications

precursor B-cell acute lymphoblastic leukemia